Velpanat

Instructions for Epclusa (Epclusa)

[Introduction]

Epclusa (trade name: Epclusa, chemical name: sofosbuvir + velpatasvir sofosbuvir + velpatasvir).

Gilead is the latest drug developed by Gilead to treat chronic hepatitis C. Velpanex was approved by the U.S. Food and Drug Administration (FDA) to be launched in the United States on June 28, 2016. On World Hepatitis Day, July 28, the first new hepatitis C drug Epclusa (Gilead) generic drug Sofosvel was officially launched in Bangladesh. Jisandai is developed, produced and sold by Beacon, a leading pharmaceutical group in Bangladesh.

[Indications and uses]

Gisanda is suitable for patients with chronic hepatitis C (Jisandai types 1-6 are applicable)

Gissanda is suitable for patients without cirrhosis or compensated cirrhosis: use Jisanda (Iklussa) alone

Gissanda is used for patients with decompensated cirrhosis: Jisanda (Iklussa) + ribavirin.

[Dosage and Administration]

One tablet once a day

Each tablet of sofosbuvir (400mg) + velpatasvir (100mg) should be taken on an empty stomach or with food.

Gissanda can be used alone or combined with ribavirin to treat chronic hepatitis C (CHC). Gsanda is as follows:

Gissanda is suitable for patients without cirrhosis or compensated cirrhosis. Patients: Ikolussa alone for 12 weeks.

For patients with decompensated cirrhosis: Ikoluxa+ribavirin for 12 weeks

< p>GISANDA cannot be administered to patients with severe renal impairment or end-stage renal disease at the recommended dosage of GISANDA

[Side Effects]

The common side effects of GISANDA are fatigue, headache, rash, throat discomfort, nausea and vomiting

[Contraindications]

GISANDA Note: Combination of GISANDA with amiodarone may cause bradycardia. Patients taking amiodarone may experience severe bradycardia, especially those who are concurrently taking beta-blockers. Iklusagi is not recommended for patients taking amiodarone. If it must be used, ECG monitoring is required

[Drug Interactions]

Rifampicin, St. John's wort, carbamazepine and other drugs will reduce the blood concentration of Ikolusagi, and it is not recommended to use it at the same time as Iklusagi.

[Drug Precautions for Special Populations]

1. Pregnant patients: The combination of Jisandai and ribavirin is contraindicated in pregnant women, and Jisandai is not suitable for use by the spouse of pregnant women. For Jisandai, please refer to the instructions for use of ribavirin and the risk information for use during pregnancy. There are insufficient data on the use of Ikrushagi III in pregnant women to determine whether Ikolusagi III poses risks during pregnancy.

2. Breastfeeding: There is insufficient data on Jisandai. Jisandai cannot determine whether Iklushajisandai exists in breast milk, nor can it be determined whether Jisandai will affect infants and young children.

3. Children: There is no information on the safety and efficacy of Jisandai. It is not recommended to use Jisandai.

4. Elderly people: Among the patients tested, Jisandai found no difference between the elderly and young people in the safety and efficacy of Jisandai drugs.

5. Patients with renal impairment: Patients with mild renal impairment do not need to adjust the dosage of GIS. In patients with severe renal impairment (eGFR<30 mL/min/1.73 m2) or end-stage renal disease requiring dialysis, the safety and efficacy of the third generation of Ikruzagib cannot be determined. There are no dosage recommendations for patients with severe renal impairment or end-stage renal disease.

[Manufacturer]

US Gilead Company Epclusa

US Mylan (Mylan) pharmaceutical factory MyHep All

Indian NATCO pharmaceutical factory Velpanat

Indian Hetero (Hydron) pharmaceutical factory Velasof

Bangladesh Beacon (Beacon) pharmaceutical factory Sofosvel